MedTrace Logo

Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy

NCT00532415 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-04-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of triamcinolone acetonide suspension when used for visualization of structures in the back of the eye during eye surgery.

Conditions

  • Vitrectomy

Interventions

DRUG

Triamcinolone Acetonide Injectable Suspension

Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2007-09-30
Completion
2007-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00532415 on ClinicalTrials.gov